Trial · NCT07569887
Exploratory Study of Cerebral Perfusion and Metabolic Alterations and Neurocognitive Disorders in Patients With Unruptured Arteriovenous Malformations Before and After Surgical Treatment
NCT07569887, Not applicable, Recruiting, University Hospital, Montpellier
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Exploratory Study of Cerebral Perfusion and Metabolic Alterations and Neurocognitive Disorders in Patients With Unruptured Arteriovenous Malformations Before and After Surgical Treatment. Trials, record NCT07569887. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07569887
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Exploratory Study of Cerebral Perfusion and Metabolic Alterations and Neurocognitive Disorders in Patients With Unruptured Arteriovenous Malformations Before and After Surgical Treatment
- NCT number
- NCT07569887
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 10 participants, estimated
- Lead sponsor
- University Hospital, Montpellier
- Conditions
- Unruptured Brain Arteriovenous Malformation
- Interventions
- 18F-FDG PET imaging, Neuropsychological Assessment
- First posted
- 2026-05-06
- Last updated
- 2026-07-07
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Standardized Uptake Value (SUV) | Before and at 6 months after surgical treatment of unruptured arteriovenous malformation | Changes in Standardized Uptake Value (SUV) measured by 18F-FDG positron emission tomography (PET) in different brain regions (arteriovenous malformation region, arteriovenous malformation hemisphere including the arteriovenous malformation region, arteriovenous malformation hemisphere excluding the arteriovenous malformation region, contralateral hemisphere) |
| Primary | Change in K1 Transfer Constant | Before and at 6 months after surgical treatment of unruptured arteriovenous malformation | Change in the K1 transfer constant, representing the transfer of the tracer from the plasma compartment to the tissue compartment, measured by 18F-FDG positron emission tomography (PET) measured in different brain regions (arteriovenous malformation region, arteriovenous malformation hemisphere including the arteriovenous malformation region, arteriovenous malformation hemisphere excluding the arteriovenous malformation region, contralateral hemisphere). Unit : mL.g-1.min-1 |
| Primary | Change in Ki Net Influx Rate Constant | Before and at 6 months after surgical treatment of unruptured arteriovenous malformation | Change in Ki net influx rate constant measured by 18F-FDG positron emission tomography (PET) in different brain regions (arteriovenous malformation region, arteriovenous malformation hemisphere including the arteriovenous malformation region, arteriovenous malformation hemisphere excluding the arteriovenous malformation region, contralateral hemisphere). Unit : mL.g-1.min-1 |
| Primary | Change in Cerebral Metabolic Rate of glucose (CMRglu) | Before and at 6 months after surgical treatment of unruptured arteriovenous malformation | Change in cerebral metabolic rate of glucose (CMRglu) measured by 18F-FDG positron emission tomography (PET) in different brain regions (arteriovenous malformation region, arteriovenous malformation hemisphere including the arteriovenous malformation region, arteriovenous malformation hemisphere excluding the arteriovenous malformation region, contralateral hemisphere). Unit : µmol.100g-¹.min-¹ |
| Secondary | Headache impact | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Headache impact assessed by the total score on the Headache Impact Test - 6 items (HIT-6) Total score between 36 and 78. A higher score indicates a greater functional impact. |
| Secondary | Visual attention and processing speed | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Visual attention and processing speed assessed by completion time on the Trail Making Test - Part A (TMT-A) |
| Secondary | Cognitive flexibility and executive control | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Cognitive flexibility and executive control assessed by completion time on the Trail Making Test - Part B (TMT-B) |
| Secondary | Inhibition and selective attention | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Inhibition and selective attention assessed by completion times and number of errors on the Stroop Test |
| Secondary | Working memory | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Working memory assessed by scores on the Digit Span subtest of the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) |
| Secondary | Global verbal episodic memory | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Global verbal episodic memory assessed by scores on the 16-item Free Recall / Cued Recall test (RL/RI-16) |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Complex Figure Copy and Recall | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07569887
GET https://conductscience.org/api/trials/v1/NCT07569887/registered